Cross-resistance to cisplatin in cells with acquired resistance to copper

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 3, 2004, Pages 239-246

  Safaei, Roohangiz ^a   Katano, Kuniyuki ^a   Samimi, Goli ^a   Naerdemann, Wiltrud ^a   Stevenson, Jennifer L ^a   Rochdi, Myriam ^a,b   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ICON Development Solutions   (United States)

Author keywords

Cisplatin; Copper; Resistance; Transport

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CATION TRANSPORT PROTEIN; CISPLATIN; COPPER; ISOPROTEIN; PLATINUM; WILSON DISEASE PROTEIN;

ARTICLE; CELL ASSAY; CELL STRAIN; CLONOGENESIS; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG RESISTANCE; DRUG TRANSPORT; DRUG UPTAKE; HEPATOMA CELL; HUMAN; HUMAN CELL; KINETICS; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; KINETICS; NEOPLASMS;

EID: 1442335459     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0736-3     Document Type: Article

References (32)

1. Amtmann E, Zoller M, Wesch H, Schilling G (2001) Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother Pharmacol 47:461
2. Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2:35
3. Andrews PA, Mann SC, Huynh HH, Albright KD (1991) Role of the Na+ , K+-ATPase in the accumulation of cis-diammine-dichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 51:3677
4. Atema A, Buurman KJ, Noteboom E, Smets LA (1993) Potentiation of DNA-adduct formation and cytotoxicity of platinum-containing drugs by low pH. Int J Cancer 54:166
5. Chen ZS, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, Saijo N, Kondo T, Akiyama S (1998) An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp Cell Res 240:312
6. Chiang CD, Song EJ, Yang VC, Chao CC (1994) Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem J 301:759
7. Endo T, Kimura O, Sakata M (2000) Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology 146:187
8. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171
9. Hromas RA, North JA, Burns CP (1987) Decreased cisplatin uptake and binding as a mechanism of resistance in L1210 leukemia cells. Cancer Lett 36:197
10. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99:14298
11. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478:23
12. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo Y-M, Rochdi M, Howell S (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559
13. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB (2003) The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64:466
14. Komatsu M, Sumizawa T, Mutoh M, Chen Z-S, Terada K, Furukawa T, Yang X-L, Gao H, Miura N, Sugiyama T, Akiyama S (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60:1312
15. Koropatnick J, Pearson J (1990) Zinc treatment, metallothionein expression, and resistance to cisplatin in mouse melanoma cells. Somat Cell Mol Genet 16:529
16. Lee KB, Parker RJ, Reed E (1995) Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance. Cancer Lett 88:57
17. Lin X, Okuda T, Holzer A, Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154
18. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH (1998) Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother Pharmacol 41:186
19. Mann SC, Andrews PA, Howell SB (1990) Short-term cis- diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25:236
20. Mann SC, Andrews PA, Howell SB (1991) Modulation of cis- diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 48:866
21. Murphy AS, Eisinger WR, Shaff JE, Kochian LV, Taiz L (1999) Early copper-induced leakage of K(+) from Arabidopsis seedlings is mediated by ion channels and coupled to citrate efflux. Plant Physiol 121:1375
22. Naredi P, Heath DD, Enns RE, Howell SB (1994) Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res 54:6464
23. Naredi P, Heath DD, Enns RE, Howell SB (1995) Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest 95:1193
24. Parker RJ, Eastman A, Bostick-Bruton F, Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87:772
25. Pena MM, Lee J, Thiele DJ (1999) A delicate balance: homeostatic control of copper uptake and distribution. J Nutr 129:1251
26. Perego P, Vande Weghe J, Ow DW, Howell SB (1997) Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatin. Mol Pharmacol 51:12
27. Romach EH, Zhao CQ, Del Razo LM, Cebrian ME, Waalkes MP (2000) Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol Sci 54:500
28. Safaei R, Howell S (2001) Cross-resistance between cisplatin, carboplatin, copper, and arsenite in human tumor cell lines. Proc Am Assoc Cancer Res 42:424
29. Sarna S, Bhola RK (1993) Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro. Arch Immunol Ther Exp 41:327
30. Schilsky ML, Stockert RJ, Kesner A, Gorla GR, Gagliardi GS, Terada K, Miura N, Czaja MJ (1998) Copper resistant human hepatoblastoma mutant cell lines without metallothionein induction overexpress ATP7B. Hepatology 28:1347
31. Tobey RA, Tesmer JG (1985) Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan. Cancer Res 45:2567
32. Zhang JG, Zhong LF, Zhang M, Ma XL, Xia YX, Lindup WE (1994) Amelioration of cisplatin toxicity in rat renal cortical slices by dithiothreitol in vitro. Hum Exp Toxicol 13:89